ArticleScientific reports2021
Capric acid secreted by Saccharomyces boulardii influences the susceptibility of Candida albicans to fluconazole and amphotericin B.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Capric Acid-Based Therapeutic Deep Eutectic Systems: A Focused Review Within the Framework of Deep Eutectic Solvents.Pharmaceuticals (Basel, Switzerland) · 2026Review
- OvercomingFrontiers in antibiotics · 2026Review
- Biotherapeutic Potential of Probiotic YeastIndian journal of microbiology · 2025Article
- Vacuole and mitochondria patch protein Mcp1 of Saccharomyces boulardii impairs the oxidative stress response of Candida albicans by regulating 2-phenylethanol.Microbial cell factories · 2025Article
- Review
- Surfactin and Capric Acid Affect the Posaconazole Susceptibility ofInternational journal of molecular sciences · 2023Article
- The Interplay betweenMicroorganisms · 2023Review
- Engineering of a probiotic yeast for the production and secretion of medium-chain fatty acids antagonistic to an opportunistic pathogenFrontiers in bioengineering and biotechnology · 2023Article
- Synergistic Effects of Capric Acid and Colistin against Colistin-Susceptible and Colistin-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- The Role of Ergosterol and Sphingolipids in the Localization and Activity ofInternational journal of molecular sciences · 2022Article
- Combination Effect of Novel Bimetallic Ag-Ni Nanoparticles with Fluconazole againstJournal of fungi (Basel, Switzerland) · 2022Article
- Antiadhesive Properties of Imidazolium Ionic Liquids Based on (-)-Menthol AgainstInternational journal of molecular sciences · 2021Article
- Lactate Like Fluconazole Reduces Ergosterol Content in the Plasma Membrane and Synergistically KillsInternational journal of molecular sciences · 2021Article
- The Role of Fatty Acid Metabolites in Vaginal Health and Disease: Application to Candidiasis.Frontiers in microbiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effect of capric acid, secreted by the probiotic yeasts Saccharomyces boulardii, was evaluated on the activities of fluconazole (FLC) and amphotericin B (AMB) against pathogenic Candida albicans fungus. The findings indicated that capric acid may be a promising additive for use in combination with FLC. A FLC-capric acid combination led to reduced efflux activity of multidrug resistance (MDR) transporter Cdr1p by causing it to relocalize from the plasma membrane (PM) to the interior of the cell. The above effect occurred due to inhibitory effect of FLC-capric acid combination of ergosterol biosynthesis. However, capric acid alone stimulated ergosterol production in C. albicans, which in turn generated cross resistance towards AMB and inhibited its action (PM permeabilization and cytoplasm leakage) against C. albicans cells. This concluded that AMB should not be administered among dietary supplements containing capric acid or S. boulardii cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.